Quest Diagnostics Incorporated $DGX Stock Acquired by Simplicity Wealth LLC

Simplicity Wealth LLC increased its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX) by 15.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,650 shares of the medical research company’s stock after purchasing an additional 3,468 shares during the quarter. Simplicity Wealth LLC’s holdings in Quest Diagnostics were worth $5,978,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Key Financial Inc raised its position in Quest Diagnostics by 1,728.6% in the 1st quarter. Key Financial Inc now owns 128 shares of the medical research company’s stock worth $25,000 after purchasing an additional 121 shares during the last quarter. Ancora Advisors LLC acquired a new position in Quest Diagnostics during the 2nd quarter worth $29,000. Frazier Financial Advisors LLC boosted its position in Quest Diagnostics by 492.9% in the 1st quarter. Frazier Financial Advisors LLC now owns 166 shares of the medical research company’s stock valued at $33,000 after buying an additional 138 shares during the last quarter. Ameritas Advisory Services LLC bought a new position in Quest Diagnostics in the 2nd quarter valued at $45,000. Finally, Dunhill Financial LLC bought a new position in Quest Diagnostics in the 2nd quarter valued at $46,000. Institutional investors and hedge funds own 88.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on DGX. Jefferies Financial Group reissued a “buy” rating and issued a $245.00 target price on shares of Quest Diagnostics in a research note on Thursday, July 23rd. Mizuho upped their price target on Quest Diagnostics from $235.00 to $260.00 and gave the company an “outperform” rating in a research note on Friday, July 24th. Weiss Ratings upgraded Quest Diagnostics from a “buy (a)” rating to a “buy (a+)” rating in a report on Wednesday. JPMorgan Chase & Co. raised their price target on Quest Diagnostics from $220.00 to $250.00 and gave the company a “neutral” rating in a report on Tuesday, July 28th. Finally, Argus set a $260.00 price objective on Quest Diagnostics in a research report on Wednesday, July 29th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, Quest Diagnostics presently has an average rating of “Moderate Buy” and an average target price of $244.27.

Insider Buying and Selling at Quest Diagnostics

In related news, CEO J. E. Davis sold 10,000 shares of Quest Diagnostics stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $242.72, for a total transaction of $2,427,200.00. Following the completion of the sale, the chief executive officer directly owned 122,423 shares of the company’s stock, valued at $29,714,510.56. The trade was a 7.55% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Mark E. Delaney sold 1,600 shares of Quest Diagnostics stock in a transaction on Tuesday, July 28th. The stock was sold at an average price of $235.18, for a total value of $376,288.00. Following the sale, the senior vice president directly owned 10,335 shares of the company’s stock, valued at approximately $2,430,585.30. This trade represents a 13.41% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 34,277 shares of company stock worth $8,316,493. Insiders own 0.88% of the company’s stock.

Quest Diagnostics News Roundup

Here are the key news stories impacting Quest Diagnostics this week:

• Positive Sentiment: Third-quarter results beat estimates: Quest reported adjusted EPS of $3.00 versus the $2.87 consensus and revenue of $3.10 billion versus expectations of $3.05 billion. Revenue increased 10% year over year, while adjusted EPS rose 15.4%, reflecting stronger testing demand and margin improvement. Quest Diagnostics Reports Third Quarter 2026 Financial Results
• Positive Sentiment: Full-year guidance was raised: Quest now expects 2026 revenue of $12.065 billion to $12.105 billion and adjusted EPS of $11.25 to $11.35, above consensus estimates of approximately $12.0 billion and $11.19, respectively. Organic requisition volume rose 14.4% in the quarter, and consumer-health revenue is expected to grow more than 30% for the year. Quest Diagnostics Earnings Takeaways
• Positive Sentiment: Valuation and momentum remain supportive: Coverage characterized DGX as potentially undervalued following the guidance increase, while Zacks highlighted the company’s long-term momentum profile. Quest Diagnostics Could Be Undervalued
• Neutral Sentiment: Deutsche Bank raised its price target to $245 from $232 but maintained a Hold rating, indicating improved expectations without a clear bullish endorsement. Deutsche Bank Adjusts Quest Diagnostics Price Target
• Negative Sentiment: Patient-data breach creates a major overhang: Quest disclosed unauthorized access to its Quanum Lab Services Manager, a system used to order tests and access results. The company confirmed that personal and health information was compromised, potentially exposing it to regulatory scrutiny, litigation, remediation costs, and reputational damage. Quest Diagnostics Patient Data Breach

Quest Diagnostics Trading Down 0.7%

DGX opened at $241.49 on Friday. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.70 and a quick ratio of 1.46. The company has a market cap of $26.65 billion, a price-to-earnings ratio of 24.05, a price-to-earnings-growth ratio of 2.17 and a beta of 0.54. The firm has a 50 day simple moving average of $237.67 and a 200 day simple moving average of $216.82. Quest Diagnostics Incorporated has a fifty-two week low of $171.18 and a fifty-two week high of $248.84.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Thursday, October 22nd. The medical research company reported $3.00 earnings per share for the quarter, beating the consensus estimate of $2.87 by $0.13. Quest Diagnostics had a net margin of 9.53% and a return on equity of 16.21%. The business had revenue of $3.10 billion for the quarter, compared to analyst estimates of $3.05 billion. During the same period in the prior year, the business posted $2.60 earnings per share. Quest Diagnostics’s revenue was up 10.0% compared to the same quarter last year. On average, sell-side analysts anticipate that Quest Diagnostics Incorporated will post 11.27 earnings per share for the current year.

Quest Diagnostics Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Wednesday, October 21st. Shareholders of record on Tuesday, October 6th were given a dividend of $0.86 per share. The ex-dividend date was Tuesday, October 6th. This represents a $3.44 annualized dividend and a dividend yield of 1.4%. Quest Diagnostics’s payout ratio is presently 34.26%.

About Quest Diagnostics

Quest Diagnostics Incorporated (NYSE: DGX) is a provider of diagnostic information services. The company performs laboratory testing that helps physicians, hospitals and other healthcare providers diagnose, treat and monitor diseases and health conditions. Its services include routine blood and other specimen testing, pathology, molecular and genetic testing, and specialized diagnostic services.

Quest Diagnostics serves a broad range of customers, including hospitals, physician practices, health plans, employers, government agencies and individual consumers.